Stock ATHA ATHIRA PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Athira Pharma, Inc.

Equities

ATHA

US04746L1044

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-24 EDT 		5-day change 1st Jan Change
2.37 USD +1.28% Intraday chart for Athira Pharma, Inc. -8.85% -2.47%
06-18 Transcript : Athira Pharma, Inc. - Special Call
06-12 Transcript : Athira Pharma, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 02:00 PM

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
GL
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
GL
Glancy Prongay & Murray LLP and Labaton Keller Sucharow LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Athira Pharma, Inc. - (NASDAQ: ATHA)
PR
Athira Pharma to Participate in Upcoming June Conferences
GL
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
GL
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
GL
Athira Pharma to Participate in Upcoming May Conferences
GL
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
GL
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's disease
AQ
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
GL
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
AQ
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
GL
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
GL
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
GL
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
GL
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
AQ
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
GL
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
AQ
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
GL
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATHA Stock
  4. News Athira Pharma, Inc.
  5. Press Releases